Monica C Serra1, Vijaya Kancherla2, Anjali Khakharia3, Latricia L Allen4, Lawrence S Phillips5, Mary K Rhee5, Peter W F Wilson6, Camille P Vaughan4. 1. Division of Geriatrics, Gerontology & Palliative Medicine and the Sam & Ann Barshop Institute for Longevity & Aging Studies, UT Health San Antonio, San Antonio, TX, USA; Department of Veterans Affairs, San Antonio Geriatric Research Education and Clinical Center, South Texas VA Health Care System, San Antonio, TX, USA. Electronic address: serram@uthscsa.edu. 2. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA. 3. Division of General Medicine and Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 4. Division of General Medicine and Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Department of Veterans Affairs, Birmingham/Atlanta Geriatric Research Education and Clinical Center, Decatur, GA, USA. 5. Atlanta VA Health Care System, Decatur, GA, USA; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 6. Atlanta VA Health Care System, Decatur, GA, USA; Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Abstract
AIM: Our objective was to assess whether increased duration of metformin therapy is associated with incident peripheral neuropathy (PN) in older Veterans with diabetes. METHODS: Using national Veterans Affairs registry data from 2002 to 2015, we examined Veterans (50 + years) with diabetes. Long-term metformin therapy was defined as prescription ≥ 500 mg/day, filled for ≥ 6 consecutive months. Metformin therapy duration was examined both as continuous and categorical measures. Incident PN was defined by medical chart review. We estimated unadjusted and adjusted (variables selecteda priori)odds ratios (OR) and 95% confidence intervals (CI) using logistic regression. RESULTS: The study included n = 210,004 individuals (mean ± SD: age: 66.2 ± 8.4 yrs, 96% male) prescribed metformin for 47.0 ± 34.0 months. Nineteen percent developed PN during follow-up. After adjusting for age, body mass index, duration of time receiving health care within the VA, smoking status, alcohol abuse, and vitamin B12 testing and treatment, the number of months of metformin treatment was associated with elevated odds for incident PN (aOR (metformin treatment - continuous) = 1.009 (95% CI = 1.009, 1.010); aOR (metformin treatment - categorical (ref: 6-<18 months): 18-<44.1 months = 1.57 (1.51-1.63), 44.1-<61 months = 2.05 (1.97-2.14), 61 + months = 2.69 (2.58-2.79), all p-values < 0.0001). CONCLUSION: Our study suggests that Veterans treated for at least 18 months with metformin are approximately 2-3 times more likely to develop PN than those treated at least six, but<18 months. Future studies are needed to determine whether the association we found may be due to a decline in vitamin B12 status following metformin initiation. Published by Elsevier B.V.
AIM: Our objective was to assess whether increased duration of metformin therapy is associated with incident peripheral neuropathy (PN) in older Veterans with diabetes. METHODS: Using national Veterans Affairs registry data from 2002 to 2015, we examined Veterans (50 + years) with diabetes. Long-term metformin therapy was defined as prescription ≥ 500 mg/day, filled for ≥ 6 consecutive months. Metformin therapy duration was examined both as continuous and categorical measures. Incident PN was defined by medical chart review. We estimated unadjusted and adjusted (variables selecteda priori)odds ratios (OR) and 95% confidence intervals (CI) using logistic regression. RESULTS: The study included n = 210,004 individuals (mean ± SD: age: 66.2 ± 8.4 yrs, 96% male) prescribed metformin for 47.0 ± 34.0 months. Nineteen percent developed PN during follow-up. After adjusting for age, body mass index, duration of time receiving health care within the VA, smoking status, alcohol abuse, and vitamin B12 testing and treatment, the number of months of metformin treatment was associated with elevated odds for incident PN (aOR (metformin treatment - continuous) = 1.009 (95% CI = 1.009, 1.010); aOR (metformin treatment - categorical (ref: 6-<18 months): 18-<44.1 months = 1.57 (1.51-1.63), 44.1-<61 months = 2.05 (1.97-2.14), 61 + months = 2.69 (2.58-2.79), all p-values < 0.0001). CONCLUSION: Our study suggests that Veterans treated for at least 18 months with metformin are approximately 2-3 times more likely to develop PN than those treated at least six, but<18 months. Future studies are needed to determine whether the association we found may be due to a decline in vitamin B12 status following metformin initiation. Published by Elsevier B.V.
Entities:
Keywords:
Aging; Metformin; Type 2 diabetes; Veteran; Vitamin B12
Authors: Vanita R Aroda; Sharon L Edelstein; Ronald B Goldberg; William C Knowler; Santica M Marcovina; Trevor J Orchard; George A Bray; David S Schade; Marinella G Temprosa; Neil H White; Jill P Crandall Journal: J Clin Endocrinol Metab Date: 2016-02-22 Impact factor: 5.958
Authors: Kathleen A McGinnis; Cynthia A Brandt; Melissa Skanderson; Amy C Justice; Shahida Shahrir; Adeel A Butt; Sheldon T Brown; Matthew S Freiberg; Cynthia L Gibert; Matthew Bidwell Goetz; Joon Woo Kim; Margaret A Pisani; David Rimland; Maria C Rodriguez-Barradas; Jason J Sico; Hilary A Tindle; Kristina Crothers Journal: Nicotine Tob Res Date: 2011-09-12 Impact factor: 4.244
Authors: Jolien de Jager; Adriaan Kooy; Philippe Lehert; Michiel G Wulffelé; Jan van der Kolk; Daniël Bets; Joop Verburg; Ab J M Donker; Coen D A Stehouwer Journal: BMJ Date: 2010-05-20
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391